(Q41634924)

English

Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris

scientific article published on November 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

1 reference

Europe PubMed Central

Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

object named as

Brogden RN

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

author name string

Markham A

2

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

publication date

1 November 1997

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

774-793

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199754050-00010

0 references

Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina Pectoris

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of myocardial infarction associated with antihypertensive drug therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular basis for the use of calcium antagonists in ischaemic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic treatment with the CA2+ channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic stable angina pectoris. Strategies for effective drug therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonlinear pharmacokinetics of mibefradil in the dog

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of calcium antagonists: dissecting the evidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Have expert panel guidelines kept pace with new concepts in hypertension?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resting state block and use independence of rat vascular muscle Ca++ channels by Ro 40-5967.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of short-term treatment of SHR with the novel calcium channel antagonist mibefradil on function of small arteries

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controversies in the diagnosis and treatment of hypertension: a personal review of JNC V.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of T-type Ca2+ channels by Ro 40-5967

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ro 40–5967, in Contrast to Diltiazem, Does Not Reduce Left Ventricular Contractility in Rats with Chronic Myocardial Infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of signal Ca2+ in dog coronary arterial vascular muscle cells by Ro 40-5967.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcium channel diversity in the cardiovascular system

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-voltage-activated T-type Ca2+ channels

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the Ca2+ Antagonist RO 40–5967 on Endothelium-Dependent Responses of Isolated Arteries

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of mibefradil on large and small coronary arteries in conscious dogs: role of vascular endothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of Ro 40-5967 and verapamil with the stably expressed alpha 1-subunit of the cardiac L-type calcium channel

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine T

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for treating hypertension: improved care or retarded progress?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/9360062

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199754050-00010

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41634924&oldid=2144683604"